HC Wainwright set a $1.00 price objective on Histogenics (NASDAQ:HSGX) in a research note issued to investors on Friday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts also recently commented on the stock. Needham & Company LLC lifted their target price on shares of Histogenics to $5.00 and gave the stock a buy rating in a research report on Thursday, September 6th. Zacks Investment Research downgraded shares of Histogenics from a hold rating to a sell rating in a research report on Thursday, October 11th. BTIG Research downgraded shares of Histogenics from a buy rating to a neutral rating and set a $3.50 target price on the stock. in a research report on Wednesday, September 5th. Finally, Brookline Cap M reiterated a buy rating on shares of Histogenics in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $3.25.

NASDAQ:HSGX traded down $0.03 during mid-day trading on Friday, hitting $0.51. 1,795,036 shares of the company’s stock were exchanged, compared to its average volume of 8,070,151. Histogenics has a fifty-two week low of $0.50 and a fifty-two week high of $3.35. The company has a market cap of $15.64 million, a PE ratio of -0.52 and a beta of 1.02.

Histogenics (NASDAQ:HSGX) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). On average, equities analysts predict that Histogenics will post -0.83 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after buying an additional 22,927 shares during the period. DRW Securities LLC acquired a new position in shares of Histogenics in the 2nd quarter worth approximately $242,000. JPMorgan Chase & Co. acquired a new position in shares of Histogenics in the 1st quarter worth approximately $320,000. Finally, Renaissance Technologies LLC lifted its position in shares of Histogenics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Further Reading: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Histogenics (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.